Literature DB >> 26242204

CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia.

Vahid Fallah Azad1, Amir Abbas Hedayati Asl1, Maryam Tashvighi2, Naghmeh Niktoreh Mofrad3, Mansoureh Haghighi1, Azim Mehrvar4.   

Abstract

Immunophenotypic changes and lineage switch between diagnosis and relapse in acute lymphoblastic leukemia are uncommon and accompanied by poor outcomes. In this report, a 12-year-old boy with diagnosis of pre-B ALL with an aberrant expression of CD 7 is described. Patient was treated with the ALL-BFM 2000 protocol and suffered an episode of relapse with a lineage switch from pre-B ALL to T cell ALL. This report concludes that presence of aberrant expression of CD7 at diagnosis of pre-B ALL can have prognostic value of lineage switch to T cell ALL at relapse.

Entities:  

Keywords:  Lineage switch; Lymphoblastic leukemia; Neoplasm antigens; Recurrence

Mesh:

Substances:

Year:  2015        PMID: 26242204     DOI: 10.1007/s00795-015-0117-0

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  17 in total

1.  Aberrant T-cell antigen expression in B lymphoblastic leukaemia.

Authors:  Shafinaz Hussein; Kamraan Z Gill; Anthony N Sireci; Adriana I Colovai; Tania Small; Foxwell N Emmons; Vundavalli V Murty; Govind Bhagat; Bachir Alobeid
Journal:  Br J Haematol       Date:  2011-09-19       Impact factor: 6.998

2.  National Immunization Program in Iran: whys and why nots.

Authors:  Maziar Moradi-Lakeh; Abdoulreza Esteghamati
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

Review 3.  Definition of acute biphenotypic leukemia.

Authors:  E Matutes; R Morilla; N Farahat; F Carbonell; J Swansbury; M Dyer; D Catovsky
Journal:  Haematologica       Date:  1997 Jan-Feb       Impact factor: 9.941

4.  Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.

Authors:  Julius M Cruse; Robert E Lewis; Samuel Pierce; John Lam; Yousef Tadros
Journal:  Exp Mol Pathol       Date:  2005-04-19       Impact factor: 3.362

5.  Lineage switch in childhood acute leukemia: an unusual event with poor outcome.

Authors:  Jorge G Rossi; Andrea R Bernasconi; Cristina N Alonso; Patricia L Rubio; Marta S Gallego; Carolina A Carrara; Myriam R Guitter; Silvia Eandi Eberle; Mariela Cocce; Pedro A Zubizarreta; María S Felice
Journal:  Am J Hematol       Date:  2012-06-08       Impact factor: 10.047

6.  Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

Authors:  M A Schorin; S Blattner; R D Gelber; N J Tarbell; M Donnelly; V Dalton; H J Cohen; S E Sallan
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

7.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

8.  Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.

Authors:  G Henze; R Fengler; R Hartmann; B Kornhuber; G Janka-Schaub; D Niethammer; H Riehm
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

9.  Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.

Authors:  C H Pui; S C Raimondi; F G Behm; J Ochs; W L Furman; N J Bunin; R C Ribeiro; P A Tinsley; J Mirro
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

10.  Lineage switch at relapse of childhood acute leukemia: a report of four cases.

Authors:  Meerim Park; Kyung Nam Koh; Bo Eun Kim; Ho Joon Im; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi; Jong Jin Seo
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.